Jumia Technologies: The Stock That Made Wall Street Giggle Today

Enter Brad Erickson, RBC Capital’s very own Nostradamus of numbers. He took his price target and gave it a good ol’ fashioned raise, bumping it from $5 to $6.50 per share. Now, don’t get too excited-he didn’t exactly light the “Buy” signal flare. Nope, he kept his rating at “sector perform,” which is analyst-speak for “eh, maybe hold onto this one unless you’ve got nothing better to do.” But oh, the man had some bullish musings tucked into his research note. And by “bullish,” I mean he sounded about as optimistic as a guy who just found out his ex-wife remarried someone richer.

MP Materials Stock: A Gonzo Trader’s Take on the Monday Mayhem

Enter Matthew Miller, CFRA’s resident oracle of doom-or maybe just another guy with too much caffeine in his system. He downgraded MP Materials from “Strong Buy” to “Buy,” which sounds like moving from a ten-course feast to a slightly smaller buffet. BUT WAIT! He also cranked up the price target from $68 to $88 per share, as if to say, “Sure, I’m slapping you around, but hey, there’s gold in them thar hills!”

Is Figma the Next Hot Tech Stock to Own?

Back in 2022, Adobe (NASDAQ: ADBE) made a bid to snap up Figma for a cool $20 billion, looking to add it to their growing empire. The regulators had other ideas, though, and put the kibosh on the deal. Now, Figma’s a free agent, floating on the market like a lone shark in a sea of minnows.

Roivant Sciences: A Market Détente Unraveled

The figures revealed a disquieting tableau: Roivant’s revenues shyly nestled just below $2.2 billion, a far cry from the bountiful nearly $8 billion accrued in the same quarter the year prior-a veritable feast turned into a meager repast. Yet the sorrow did not halt at the revenue line; the company endured a descent into the abyss of a net loss, eclipsing $223 million-amounting to $0.33 per share-where once it had basked in the glow of a $95 million profit.

Ken Griffin’s Stock Picks: A Contrarian’s Take

The SEC makes people like Griffin disclose their stock holdings every quarter. These disclosures, called 13F filings, are treated by many investors as though they’re sacred texts handed down from Mount Sinai. But let me tell you something about sacred texts-they rarely mention Charles Schwab or Keurig Dr Pepper. Here’s what Griffin’s hoarding these days, in case you were wondering:

Tesla’s Soaring Shares: A Tale of Robots and Revenue

Barron’s report on elongated wait times for the Model Y-now stretching from one to three weeks to a grotesque four to six-has been interpreted by some as evidence of renewed demand. Yet let us not forget: this is a company whose sales have hemorrhaged year-over-year in 2024, a season of Lent for EV enthusiasts. The tax credit’s impending expiration, that alms of $7,500, may yet drive a final stampede of buyers, as frantic as a horseman fleeing the Four Horsemen.

Insider Sale: A Financial Harvest in Alaska’s Skies

What does this sale mean for the alignment of insiders?
By the dawn of July 29, 2025, Andrew R. Harrison still held 18,930 shares-a tether, though loosened, to the fate of Alaska Air Group. Yet one wonders if such tethers are strong enough to hold when the winds of profit blow hard against them.

Can $30,000 Turn Into a Million Bucks? Let’s Get Real (and Silly)

Now, if picking individual stocks feels as daunting as choosing which fork to use at a fancy dinner party, fear not! The S&P 500 is here to save your sanity-and possibly your portfolio. This index isn’t just any collection of companies; no sir, it’s like the Avengers of the stock market, minus the spandex. Only the crème de la crème make the cut, and when they falter (cue dramatic organ music), they’re shown the door faster than a bad vaudeville act.

Moderna’s Three Dashedly Important Dilemmas

But fear not! For all is not lost in the realm of mRNA. Whether Moderna can rebound and reclaim its former glory depends on three rather crucial developments, which we shall now examine with the enthusiasm of a man discovering a forgotten cigar case. Let us begin, if you’ll permit me, with the first.

AppLovin’s Comedy of Shorts and Surges

Enter the trio of schemers: Fuzzy Panda, Muddy Waters, and Culper, who, with the solemnity of philosophers, have declared war on AppLovin’s Axon 2.0, its AI adtech marvel. “Treason!” they cry, alleging privacy violations and clandestine app installations. Yet, what have they gained but a chorus of yawns from the mighty Alphabet and Apple? One might say their plots are as effective as a screen door on a submarine.